tbuckley/cabot-search huggingface dataset:
Abstract 16311: Inhibition of TGF-Beta in the Presence of Elevated Angiotensin II is Associated With Increased Incidence of Thoracic Aortic Dissection in Apoe Deficient and Wild Type Mice
Authors: Malcolm West, Maria Nataatmadja, Sulistiana Prabowo, Jennifer West, Philip Walker
Journal: Circulation (2010)

Aortic aneurysm is a life threatening condition due to the lack of symptoms and high incidence of dissection. Recent studies have shown that inhibition of TGF-beta using TGF-beta neutralising antibody (TGFB-NAB) resulted in inhibition of thoracic aortic aneurysm (TAA) and dissection (TAD) in Marfan mouse model. Inhibition of TGF-beta using losartan was able to inhibit abdominal aortic aneurysm (AAA) and dissection (AAD) in ApoE−/− infused with Angiotensin (Ang)II for 2 weeks. TGFB-NAB induced AAA and AAD in the wild type mice (C57) infused with AngII for 4 weeks. This study aimed to differentiate the effect of TGF-beta inhibition in thoracic and abdominal aorta with/without AngII infusion in the absence/presence of genetic inheritance. Male 12 week old ApoE−/− and C57 (n=10/group) were infused with either saline or subpressor dose of AngII (1000mg/kg/min) for 4 weeks in the presence/absence of TGF-beta inhibitor (TGFB-NAB; 1mg/kg/2 week or losartan; 30mg/kg/day). At the end of the experiment or at the time of aortic dissection thoracic and abdominal aorta was collected and histological sections were used to determine the presence and location of aortic dissection and/or wall structure remodelling. Saline infusion with/without TGFB-NAB or Losartan did not cause any AAD or TAD in all groups. AngII infusion in ApoE−/− resulted in 10% AAD. AngII and TGFB-NAB resulted in 10% AAD and 30% TAD while AngII and Losartan resulted in 20% TAD. In C57 AngII with/without Losartan did not cause AAD or TAD. AngII and TGFB-NAB resulted in 20% TAD. Minimal inflammatory cells were present in the arterial wall of all groups. This study indicated that the cause of AAD and TAD is diverse. AngII induced AAD in ApoE−/− and Losartan was able to inhibit AngII induced AAD while TGFB-NAB failed to prevent it. Inhibition of TGF-beta using TGFB-NAB and Losartan induced TAD in AngII infused ApoE−/−. AngII alone did not cause AAD or TAD in C57. Only when TGF-beta was inhibited with TGFB-NAB was AngII able to induced TAD. In conclusion TGF-beta inhibition using TGFB-NAB and Losartan in the presence of AngII elevation resulted in TAD but not AAD. The effect of TGF-beta inhibition was dependent on additional supporting factors including genetic background and exogenous AngII infusion.
Ichthyosiform erythroderma and cardiomyopathy: report of two cases and review of the literature
Authors: None Hoeger, None Adwani, None Whitehead, None Finlay, None Harper
Journal: British Journal of Dermatology (1998)

We report two children with ichthyosiform erythroderma who at the ages of 9 weeks and 8 years, respectively, developed dilated cardiomyopathy, which was fatal in one and required heart transplantation in the other. A link between these conditions is considered likely, either as a primary genetic syndrome or secondary to micronutrient deficiency and/or infection. Owing to its insidious onset, cardiomyopathy may be overlooked, or symptoms attributed to the other conditions such as severe infections and failure to thrive that are common in these patients. We therefore recommend that children with congenital erythroderma are monitored closely, clinically and with echocardiography, for cardiomyopathy.
Abstract 16588: Adiposity, Blood Pressure, and Incidence of Stroke Subtypes Among 0.5 Million Adult Chinese With 7 Years of Follow-Up
Authors: Zhengming Chen, Andri Iona, Yu Guo, Margaret Smith, Robert Clarke, Sarah Lewington, Yiping Chen, Iona Millwood, Zheng Bian, Robin Walters, Yunlong Tang, Sarah Parish, Rory Collins, Junshi Chen, Richard Peto, Liming Li
Journal: Circulation (2014)

Introduction: Stroke is a major cause of mortality and disability worldwide, with particularly high rates in China that cannot be explained by known risk factors. Moreover, uncertainty remains about the associations of adiposity with different stroke subtypes. Methods: China Kadoorie Biobank prospective study includes 512,891 people aged 30-79 years at recruitment in 2004-8 from 10 regions of China, with 20,000 resurveyed to assess regression dilution. During ~7 years of follow-up, ~30,000 first strokes were recorded among people without prior CVD (with ~75% confirmed by imaging). Cox regression related adiposity and usual systolic blood pressure (SBP) to stroke incidence, adjusting for age, sex, education, region, smoking, alcohol and other factors. Results: Mean BMI was 24 kg/m2; 4% had BMI>30. Mean SBP/DBP was 131/78 mmHg. Adiposity was more strongly related to blood pressure than in Western populations, with 10 kg/m2 higher BMI yielding ~20 mmHg higher SBP. Each 20 mmHg higher usual SBP was associated...
Abstract 125: "Load &amp; Go" Criteria in Out-of-Hospital Cardiac Arrest Patients for the Use of Emergency-Extracorporal Life Support at the Emergency Department
Authors: Michael Poppe, Andreas Schober, Christoph Weiser, Patrick Sulzgruber, Philip Datler, Markus Keferböck, Sebastian Zeiner, Elisabeth Lobmeyr, Alexander Nürnberger, Raphael Van Tulder, Mario Krammel, Fritz Sterz
Journal: Circulation (2014)

Background: The outcome of patients after OHCA has been poor. The probability of return of spontaneous circulation decreases over time. New therapeutic attempts like E-ECLS at the ED are tried to improve outcome of selected cases. The "Vienna Cardiac Arrest Registry" (VICAR) was introduced August 1, 2013 to collect Utstein-style data. Our aim was to identify those patients which might fulfill ‘load&amp;go’ criteria for E-ECLS at the ED after OHCA. Methods: Therefore VICAR was retrospectively analysed for following criteria: age&lt;75a;witnessed OHCA; basic life support (BLS); ventricular fibrillation/ventricular tachycardia (VF/VT); no return of spontaneous circulation (ROSC) within 15min CPR by EMS. Patients had to fulfill all these criteria. Results: Overall 701 patients were registered from August 1, 2013 to April 30, 2014. Excluded were because of poor documentation 26(4%) patients, because of missing criteria data 49(7%) and because they were younger than 18 years 7 (1%). The final analysis included 619(88%) patients; of those 68(11%) were transported under ongoing CPR to the ED. Moreover E-ECLS was applied in 15 patients at the ED. Conclusion: We found 30 (5%) patients to fulfill ’load &amp; go’ criteria. Of 68 patients, who were transported with ongoing CPR to the ED only 8 (8%) met the criteria. Further promotion of these criteria within the ambulance crews is needed. Maybe these criteria could then serve as a decision support for emergency physicians/paramedics, which patients to transport under ongoing CPR to the ED for E-ECLS.
TETANUS, A SEVERE CASE WITH RECOVERY
Authors: F B TAYLOR, R G PARSONS, H E HANSEN
Journal: Annals of Internal Medicine (1951)

Case Reports1 November 1951TETANUS, A SEVERE CASE WITH RECOVERYFLETCHER B. TAYLOR, M.D., F.A.C.P., ROBERT G. PARSONS, M.D., HOWARD E. HANSEN, M.D.FLETCHER B. TAYLOR, M.D., F.A.C.P.Search for more papers by this author, ROBERT G. PARSONS, M.D.Search for more papers by this author, HOWARD E. HANSEN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-35-5-1134 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCASE REPORTOn April 8, 1948, a 17 year old boy scratched the skin on the medial side of his ankle while running a hurdle race. The small wound bled very little and was nearly healed three days later. On April 12 he struck the abrasion with the spike of his track shoe and reopened it. On that day he began to have diffuse soreness in the low back. During the next three days, the soreness in the back became more severe and more general. With rapid increase in this soreness and in muscle tension, he was hardly able to... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication July 19, 1949.From the Isolation Department of Highland Alameda County Hospital, Oakland, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1951Volume 35, Issue 5Page: 1134-1137KeywordsAnklesMyalgiaRacial and ethnic issuesRunningTetanus Issue Published: 1 November 1951 PDF downloadLoading ...
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia
Authors: William T. Carpenter, Robert W. Buchanan
Journal: JAMA Psychiatry (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma
Authors: Kairong Shi, Jianping Li, Zhonglian Cao, Ping Yang, Yue Qiu, Bo Yang, Yang Wang, Yang Long, Yayuan Liu, Qianyu Zhang, Jun Qian, Zhirong Zhang, Huile Gao, Qin He
Journal: Journal of Controlled Release (2015)
Ozone and Asthma
Authors: Albert Donnay
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Authors: Matthew M. Gubin, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber
Journal: Journal of Clinical Investigation (2015)

It is now well established that the immune system can recognize developing cancers and that therapeutic manipulation of immunity can induce tumor regression. The capacity to manifest remarkably durable responses in some patients has been ascribed in part to T cells that can (a) kill tumor cells directly, (b) orchestrate diverse antitumor immune responses, (c) manifest long-lasting memory, and (d) display remarkable specificity for tumor-derived proteins. This specificity stems from fundamental differences between cancer cells and their normal counterparts in that the former develop protein-altering mutations and undergo epigenetic and genetic alterations, resulting in aberrant protein expression. These events can result in formation of tumor antigens. The identification of mutated and aberrantly expressed self-tumor antigens has historically been time consuming and laborious. While mutant antigens are usually expressed in a tumor-specific manner, aberrantly expressed antigens are often shared between cancers and, therefore, in the past, have been the major focus of therapeutic cancer vaccines. However, advances in next-generation sequencing and epitope prediction now permit the rapid identification of mutant tumor neoantigens. This review focuses on a discussion of mutant tumor neoantigens and their use in personalizing cancer immunotherapies.
Group legal action launched over retained organs
Authors: Clare Dyer
Journal: BMJ (2001)

Bereaved families who were shocked to discover that their relatives' organs had been retained after hospital postmortem examinations and not buried with their bodies won the go-ahead at the High Court in London last week for a mass action for compensation.

Four hundred people have so far consulted 17 firms of solicitors, but lawyers said the claim could include many more.

A High Court procedural judge, Chief Master Turner, made a group litigation order last week, enabling all the claims to be dealt …
Poised to Challenge Need for Sleep, "Wakefulness Enhancer" Rouses Concerns
Authors: Brian Vastag
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A radiation hybrid map of mouse genes
Authors: Thomas J. Hudson, Deanna M. Church, Simon Greenaway, Huy Nguyen, April Cook, Robert G. Steen, William J. Van Etten, Andrew B. Castle, Mark A. Strivens, Pamela Trickett, Christine Heuston, Claire Davison, Anne Southwell, Rachel Hardisty, Anabel Varela-Carver, Andrew R. Haynes, Patricia Rodriguez-Tome, Hirofumi Doi, Minoru S.H. Ko, Joan Pontius, Lynn Schriml, Lukas Wagner, Donna Maglott, Steve D.M. Brown, Eric S. Lander, Greg Schuler, Paul Denny
Journal: Nature Genetics (2001)
Intraarticular Hip Injection and Early Revision Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study
Authors: Bheeshma Ravi, Benjamin G. Escott, David Wasserstein, Ruth Croxford, Simon Hollands, J. Michael Paterson, Hans J. Kreder, Gillian A. Hawker
Journal: Arthritis & Rheumatology (2014)

Objective Therapeutic intraarticular injections are used in the management of hip osteoarthritis (OA). Some studies suggest that their use increases the risk of infection and subsequent revision surgery after primary total hip arthroplasty (THA), while others do not. We undertook this study to clarify the relationship between prior intraarticular injection and the risk of complication in a subsequent primary THA. Methods In a cohort of patients with hip OA who underwent a primary elective THA between 2002 and 2009, we identified those who received ≥1 intraarticular injection performed by a radiologist in the 5 years preceding their THA. Multivariable Cox proportional hazards models were used to determine the relationship between receipt of a presurgical injection (no injection, 1–5 years prior to THA, or &lt;1 year prior to THA) and the occurrence of postsurgical joint infection and revision THA in the following 2 years, while controlling for confounders. Results Of 37,881 eligible THA recipients, 2,468 (6.5%) received an intraarticular injection performed by a radiologist within 5 years of their THA (1,691 at &lt;1 year, 777 at 1–5 years). Controlling for age, sex, comorbidity, frailty, income, and provider volume, those who had an injection in the year preceding surgery were at increased risk of infection (adjusted hazard ratio [HR] 1.37, P = 0.03) and revision THA (adjusted HR 1.53, P = 0.03) within 2 years of the primary THA, relative to patients who did not. The association between prior injection and revision arthroplasty was attenuated and became nonsignificant (adjusted HR 1.41, P = 0.13) after occurrence of postoperative infection was controlled for in the regression model. No effect was found for injection 1–5 years prior to surgery. Conclusion Intraarticular injection in the year preceding THA independently predicted increased risk of infection leading to early revision surgery. Further studies are warranted to elucidate explanations for these findings.
Helsinki Discord? A Controversial Declaration
Authors: B Vastag
Journal: JAMA (2000)

WASHINGTON—A long-awaited fifth revision of the Declaration of Helsinki, widely acknowledged as the foundation of medical research ethics, is receiving mixed reactions for discouraging placebos in clinical trials and mandating researchers to provide “best proven” therapy to participants after a trial. Patient protection advocates, who lobbied hard for the new language, hail the revision as a major step toward abolishing what they see as unethical research, especially in developing nations. Delon Human, MD, secretary general of the World Medical Association (WMA), which put forth the declaration, is equally enthusiastic. He says the revision is an ideal—not a “manual of protocols and procedures”—but that it sets an ethical standard “which I don’t think can be set high enough.” Or can it be? Some researchers and bioethicists are calling the recommendations on placebo use unwarranted and unnecessary, a possible bane to future research. And the US agencies responsible for protecting patients in medical studies, namely the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS), are noncommittal about whether they will subscribe to the revision, which provides no means of enforcement. “I think it’s scientifically and ethically incorrect,” said Robert Temple, MD, director of the FDA’s Office of Drug Evaluation. “We’ll have to see if the Declaration of Helsinki remains the ethical standard for the world.” Temple cautioned that he was speaking only for himself, not for the FDA, but he later added that he would try to persuade others in the agency to his point of view. Greg Koski, MD, PhD, director of the DHHS’s Office for Human Research Protections, simply said, “This is an area of active discussion in the department. There will be more information forthcoming as we try to offer some guidance to researchers.” Both the DHHS and FDA are reviewing the new declaration with one eye on their own policies and another on parallel ethics statements being prepared by the National Bioethics Advisory Commission and the Commission for International Organizations of Medical Sciences, part of the World Health Organization. If these groups issue statements straying from Helsinki’s policy—a very real possibility, according to several sources—researchers will have to play “pick the doctrine” when planning new studies.
AMYOPLASIA CONGENITA: CASE REPORT AND REVIEW OF LITERATURE
Authors: G B LEMMON, A D VAIL
Journal: Annals of Internal Medicine (1954)

Case Reports1 October 1954AMYOPLASIA CONGENITA: CASE REPORT AND REVIEW OF LITERATUREG. BRUCE LEMMON JR., M.D., A. DENTON VAIL, M.D.G. BRUCE LEMMON JR., M.D.Search for more papers by this author, A. DENTON VAIL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-4-836 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptI. INTRODUCTIONAmyoplasia congenita is a condition rarely reported in the American literature, only three such references being found.1, 2, 3Approximately 100 cases have been collected from the available American and European literature, with the possibility of duplication in some reports. The condition, which has also been called dysmyoplasia congenita, multiple articular rigidity, arthrogryposis multiplex congenita, and myodystrophia fetalis deformans, was first described by A. G. Otto4in 1841. However, it remained for Rosenkranz5in 1905 and Rocher6in 1913 to present sizable collections of cases and for Sheldon7in 1932 to give a comprehensive discussion. This case is...Bibliography1. Stern WG: Arthrogryposis multiplex congenita, J. A. M. A. 81: 1507-1510, 1923. CrossrefGoogle Scholar2. Katzeff M: Arthrogryposis multiplex congenita, Arch. Surg. 46: 673-676, 1943. CrossrefGoogle Scholar3. HillmanJohnson JWJT: Arthrogryposis multiplex congenita in twins, J. Bone and Joint Surg. 34A: 211-214, 1952. CrossrefGoogle Scholar4. Otto , cited by Middleton.9 Google Scholar5. Rosenkranz , cited by Katzeff.2 Google Scholar6. Recher HL: Les raideurs articulaires congénitales multiples, J. de méd. de Bordeaux 84: 772-780, 1913. Google Scholar7. Sheldon W: Amyoplasia congenita, Arch. Dis. Childhood 7: 117-136, 1932. CrossrefMedlineGoogle Scholar8. Brandt S: Case of arthrogryposis multiplex congenita anatomically appearing as foetal spinal muscular atrophy, Acta pædiat. 34: 365-381, 1947. CrossrefMedlineGoogle Scholar9. Middleton DS: Studies on prenatal lesions of striated muscle as a cause of congenital deformity, Edinburgh M. J. 41: 401-442, 1934. MedlineGoogle Scholar10. Gilmore JR: Amyoplasia congenita, J. Path. and Bact. 58: 675-685, 1946. CrossrefMedlineGoogle Scholar11. Weber FP: Amyoplasia congenita, M. Press 218: 593-595, 1947. MedlineGoogle Scholar12. Roberts JA: The inheritance of a lethal muscle contracture in the sheep, J. Genetics 21: 57-69, 1929. CrossrefGoogle Scholar13. Brain R: Diseases of the nervous system, 1947, Oxford University Press, London, p. 610. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Springfield, Missouri*Received for publication October 27, 1953. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAmyoplasia revisited 1 October 1954Volume 41, Issue 4Page: 836-841 ePublished: 1 December 2008 Issue Published: 1 October 1954 PDF downloadLoading ...
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Authors: Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Journal: Journal of Clinical Oncology (2023)

The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against